Drug Trial Radar · NCT07857265
Mass Balance Study of [14C]DA-302168S in Healthy Chinese Adult Male Participants
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Nov 20, 2026
Primary completion
Dec 20, 2026
Study completion Dec 20, 2026
Sponsor
- Lead sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In this study, a single dose of \[14C\] radiolabelled DA-302168S will be administered orally. The main purpose of this study is to find out how much of DA-302168S and its metabolites pass from blood into urine and feces, and characterize the metabolic profile and routes of excretion of oral \[14C\] DA-302168S.
Conditions
- Healthy Adult Subjects
Interventions
[14C] DA-302168SDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total recovery of DA-302168S radioactivity in urine and feces, following oral administration of [14C] DA-302168STime frame: Predose up to Day 8 after administration of [14C]DA-302168S
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.